Related Experiment Video
Updated: Sep 10, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Cardiovascular Disease Update: Heart Failure Update
Kevin A Bobeck1, Anthony M Recidoro2, Joseph M Sapoval3
1Walter Reed National Military Medical Center, Bethesda, MD.
Insights
Heart failure (HF) management involves early diagnosis and staging. Effective treatments for reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) improve patient outcomes and reduce hospitalizations.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Heart failure (HF) is a prevalent condition where the heart cannot pump blood effectively, impacting millions globally.
- Increasing prevalence, hospitalizations, and mortality rates highlight the urgent need for effective HF management strategies.
- HF classification includes HF with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF), guiding treatment approaches.
Purpose of the Study:
- To review current diagnostic and therapeutic strategies for heart failure.
- To emphasize the importance of early diagnosis and staging in managing HF.
- To discuss the role of pharmacologic and non-pharmacologic interventions in improving HF patient outcomes.
Main Methods:
- Review of guideline-directed medical therapies for HFrEF.
- Analysis of comorbidity management strategies, including obesity treatment in HFpEF.
- Inclusion of advanced therapies, cardiac rehabilitation, and supportive interventions.
Main Results:
- Guideline-directed medical therapy significantly reduces morbidity, mortality, and hospitalizations in HFrEF patients.
- Management of comorbidities, such as obesity with GLP-1 receptor agonists in HFpEF, improves outcomes.
- Comprehensive care including advanced therapies and supportive interventions enhances quality of life.
Conclusions:
- Early diagnosis and staging are crucial for effective heart failure management.
- Multifaceted treatment strategies, encompassing guideline-directed medical therapy, comorbidity management, and supportive care, are essential for reducing HF progression and improving survival.
- Continued focus on both pharmacologic and non-pharmacologic approaches is vital for optimizing patient outcomes in heart failure.
Abstract:
Heart failure (HF) is a clinical condition characterized by the heart's inability to pump blood effectively enough to meet the body's metabolic demands; typically this happens because of impaired ventricular filling or ejection. HF affects millions of people in the United States, with increasing prevalence, hospitalizations, and deaths. Classification of HF by left ventricular ejection fraction divides it into HF with preserved ejection fraction (HFpEF), mildly reduced ejection fraction, and reduced ejection fraction (HFrEF). Early diagnosis and appropriate staging, using tools such as natriuretic peptides and echocardiography, are essential for identifying HF and implementing effective treatment. In patients with HFrEF, guideline-directed medical therapy, comprising renin-angiotensin system inhibitors, beta blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, has demonstrated reductions in morbidity, mortality, and hospitalizations. Management of comorbidities such as the use of glucagon-like peptide-1 receptor agonists for obesity in patients with HFpEF has improved outcomes. Advanced therapies, cardiac rehabilitation, and supportive interventions, including vaccinations and mental health screening, contribute to improved patient quality of life. Focusing on pharmacologic and nonpharmacologic strategies is essential to reduce HF progression, minimize hospitalizations, and improve overall survival.
More Related Videos
Related Concept Videos
Heart Failure I: Introduction
Pathophysiology of Heart Failure
Cardiomyopathy V: Interprofessional Care
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology

